Nello Mainolfi - 08 Oct 2021 Form 4 Insider Report for Kymera Therapeutics, Inc. (KYMR)

Role
Chief Executive Officer, Director
Signature
/s/ Bruce Jacobs, as Attorney-in-Fact
Issuer symbol
KYMR
Transactions as of
08 Oct 2021
Net transactions value
-$2,604,696
Form type
4
Filing time
12 Oct 2021, 16:30:47 UTC
Previous filing
19 Aug 2021
Next filing
16 Dec 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KYMR Common Stock Options Exercise $86,412 +41,544 +8.9% $2.08* 505,743 08 Oct 2021 Direct
transaction KYMR Common Stock Sale $1,179,868 -21,236 -4.2% $55.56 484,507 08 Oct 2021 Direct F1, F2
transaction KYMR Common Stock Sale $532,391 -9,369 -1.9% $56.82 475,138 08 Oct 2021 Direct F1, F3
transaction KYMR Common Stock Sale $119,046 -2,078 -0.44% $57.29 473,060 08 Oct 2021 Direct F1, F4
transaction KYMR Common Stock Sale $469,463 -7,920 -1.7% $59.28 465,140 08 Oct 2021 Direct F1, F5
transaction KYMR Common Stock Sale $40,412 -670 -0.14% $60.32 464,470 08 Oct 2021 Direct F1, F6
transaction KYMR Common Stock Sale $16,767 -271 -0.06% $61.87 464,199 08 Oct 2021 Direct F1
transaction KYMR Common Stock Options Exercise $13,428 +6,456 +1.4% $2.08* 470,655 11 Oct 2021 Direct
transaction KYMR Common Stock Sale $306,044 -5,712 -1.2% $53.58 464,943 11 Oct 2021 Direct F1, F7
transaction KYMR Common Stock Sale $40,546 -744 -0.16% $54.50 464,199 11 Oct 2021 Direct F1, F8

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KYMR Stock Option (Right to Buy) Options Exercise $0 -41,544 -54% $0.000000 35,181 08 Oct 2021 Common Stock 41,544 $2.08 Direct F9
transaction KYMR Stock Option (Right to Buy) Options Exercise $0 -6,456 -18% $0.000000 28,725 11 Oct 2021 Common Stock 6,456 $2.08 Direct F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $55.10 to $56.09. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $56.19 to $57.185. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F4 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $57.20 to $58.14. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F5 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $58.90 to $59.81. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F6 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $59.91 to $60.61. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F7 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $53.19 to $54.16. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F8 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $54.28 to $54.60. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F9 The shares underlying this stock option shall vest upon the achievement of specified performance-based milestones.